(:AGTC)

Dec 01, 2022 07:00 am ET
Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today the successful completion of the previously announced tender offer (the “Offer”) to purchase all of the issued and outstanding shares of common stock...
Nov 29, 2022 08:00 am ET
Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today that a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”) has extended the expiration of its previously announced tender offer to purchase...
Nov 28, 2022 08:30 am ET
*FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER*
Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona Limited portfolio company has commenced a tender offer to purchase all outstanding shares of AGTC...
Nov 22, 2022 04:05 pm ET
*REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *REMINDER*
Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona Limited portfolio company has commenced a tender offer to purchase all outstanding shares of AGTC...
Nov 14, 2022 04:01 pm ET
Applied Genetic Technologies Corporation Urges Shareholders to Tender Their Shares by November 28, 2022
Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, sent the following letter to stockholders: A Syncona Limited portfolio company has commenced a tender offer to purchase all outstanding...
Nov 14, 2022 01:15 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates Applied Genetic Technologies Corporation
NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Applied Genetic Technologies Corporation ("Applied Genetic" or the "Company") (NASDAQ: AGTC), in connection with the proposed acquisition of the Company via tender offer.  Under the tender offer, the Company's shareholders will receive $0.34 in cash for each share of Applied Genetic common stock owned, plus one non-tradeable contingent value right ("CVR").  The transaction is valued at approximately $23.5 million.
Nov 08, 2022 01:39 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OYST, OUST, AGTC
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Oyster Point Pharma, Inc. (NASDAQ:...
Nov 03, 2022 06:00 pm ET
APPLIED GENETIC TECHNOLOGIES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Genetic Technolog
NEW ORLEANS, Nov. 3, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Applied Genetic Technologies Corporation (NasdaqGM: AGTC) to Syncona Limited. Under the terms of the proposed transaction, shareholders of Applied will receive only $0.34 in cash for each share of Applied that they own, plus potential future aggregate cash payments of up to $0.73 per share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whe
Nov 03, 2022 08:30 am ET
Applied Genetic Technologies Corporation Reminds Shareholders to Tender Their Shares by November 28, 2022
Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, sent the following letter to shareholders: On October 23, 2022, we announced that AGTC entered into a definitive agreement, pursuant to...
Oct 28, 2022 08:24 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USER, AIMC, AGFS, AGTC
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: UserTesting, Inc. (NYSE: USER)’s...
Oct 27, 2022 07:15 pm ET
EQUITY ALERT: The M&A Class Action Firm Announces the Investigation of Applied Genetics Technologies Corp. - AGTC
NEW YORK, Oct. 27, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Applied Genetics Technologies Corp. (AGTC), relating to its proposed acquisition by Syncona Limited. Under the terms of the agreement, AGTC shareholders are expected to receive $0.34 in cash plus potential future cash payments of up to $0
Oct 26, 2022 05:24 pm ET
Syncona Commences Tender Offer for All Outstanding Shares of Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation (Nasdaq: AGTC) (“AGTC” or the “Company”) and a newly established portfolio company of Syncona Limited (“Syncona”), a leading healthcare company focused on founding, building and funding global leaders in...
Oct 25, 2022 09:51 pm ET
APPLIED GENETIC TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Genetic Technolog
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Genetic Technologies Corporation (NasdaqGM: AGTC) to Syncona Limited. Under the terms of the proposed transaction, shareholders of Applied will receive only $0.34 in cash for each share of Applied that they own, plus potential future aggregate cash payments of up to $0.73 per share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Oct 25, 2022 10:30 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LMST, PEBO, HVBC, MYOV, AGTC
NEW YORK, Oct. 25, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 24, 2022 09:33 am ET
Shareholder Alert: Ademi LLP investigates whether Applied Genetic Technologies Corporation has obtained a Fair Price in its transaction with Syncona Limited
MILWAUKEE, Oct. 24, 2022 /PRNewswire/ -- Ademi LLP is investigating AGTC (NASDAQ: AGTC) for possible breaches of fiduciary duty and other violations of law in its transaction with Syncona Limited. 
Oct 24, 2022 08:14 am ET
AGTC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Applied Genetic Technologies Corporation Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Applied Genetic Technologies Corporation (NASDAQ: AGTC) to Syncona Limited for $0.34 per share in cash plus potential future aggregate cash payments of up to $0.73 per share pursuant to contingent value rights is fair to Applied Genetic shareholders.
Oct 23, 2022 10:05 pm ET
Syncona to Acquire Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating...
Sep 01, 2022 08:00 am ET
AGTC to Participate in Upcoming Investor Conferences
Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the...
Aug 01, 2022 04:05 pm ET
AGTC to Participate in Upcoming Investor Conferences
Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the...
Jul 26, 2022 08:00 am ET
AGTC Receives Positive Type C Meeting Feedback from the FDA for the Company’s Design and Operating Procedures of its Planned cGMP Manufacturing Facility
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and...
Jul 12, 2022 09:30 pm ET
AGTC Announces Pricing of $10 Million Underwritten Public Offering
Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of...
Jul 12, 2022 04:01 pm ET
AGTC Announces Proposed Underwritten Public Offering
Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of...
Jul 07, 2022 08:00 am ET
AGTC to Present at Upcoming American Society of Retina Specialists Annual Meeting
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial...
Jun 08, 2022 08:00 am ET
AGTC Announces Key Appointments to Leadership Team
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial...
Jun 06, 2022 08:00 am ET
AGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa at the 45th Macula Society Annual Meeting
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial...
Jun 01, 2022 08:00 am ET
AGTC Announces Age-Related Macular Degeneration Scientific Advisory Board
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial...
May 18, 2022 08:00 am ET
AGTC to Present at the H.C. Wainwright Global Investment Conference
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial...
May 16, 2022 04:01 pm ET
AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial...
May 10, 2022 08:00 am ET
AGTC Hosts Topping Off Ceremony for Gene Therapy Manufacturing Facility to Celebrate the Building’s Structural Completion
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial...
May 04, 2022 08:00 am ET
Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 Presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial...
May 02, 2022 04:33 pm ET
AGTC to Present Preclinical Research Supporting Gene Therapy Platform in Frontotemporal Dementia at the 25th Annual Meeting of the American Society of Gene & Cell Therapy
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial...
Apr 14, 2022 08:00 am ET
AGTC to Present at Cell & Gene Meeting on the Mediterranean
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial...
Apr 04, 2022 04:45 pm ET
AGTC to Showcase Interim Findings from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial...
Mar 22, 2022 08:45 am ET
AGTC Announces Pricing of Public Offering of Common Stock
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating...
Mar 21, 2022 04:01 pm ET
AGTC Announces Proposed Public Offering of Common Stock
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating...
Mar 08, 2022 04:05 pm ET
AGTC to Participate in Upcoming Investor Conferences
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating...
Feb 14, 2022 07:00 am ET
AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating...
Feb 08, 2022 07:00 am ET
AGTC Announces Robust Improvements in Visual Sensitivity in Adult and Pediatric Patients, and Plans to Continue Clinical Development of AGTC-401 in Patients with CNGB3 Achromatopsia
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating...
Feb 07, 2022 08:00 am ET
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating...
Jan 11, 2022 08:00 am ET
AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating...
Jan 04, 2022 08:00 am ET
AGTC to Participate in the H.C. Wainwright BioConnect 2022 Conference
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating...
Dec 06, 2021 08:00 am ET
AGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of Directors
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating...
Nov 16, 2021 08:00 am ET
AGTC Appoints Abraham Scaria, Ph.D., as Chief Science Officer
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced the...
Nov 12, 2021 08:00 am ET
AGTC Presents Data from Ongoing Phase 1/2 Trial of AGTC-501 at Upcoming American Academy of Ophthalmology 2021 Annual Meeting
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced the...
Nov 11, 2021 08:00 am ET
AGTC Appoints Hope D’Oyley-Gay as General Counsel
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced the...
Nov 10, 2021 04:18 pm ET
Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended September 30, 2021 and provided an update on its product...
Nov 10, 2021 08:00 am ET
AGTC to Participate in the Stifel 2021 Virtual Healthcare Conference
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that...
Nov 09, 2021 07:00 am ET
AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced...
Nov 02, 2021 08:00 am ET
AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 9, 2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases, today announced that it...
Oct 19, 2021 08:00 am ET
AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue...
Oct 14, 2021 05:00 pm ET
AGTC Announces Two Key Leadership Team Appointments
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced the...
Oct 12, 2021 08:00 am ET
AGTC to Present at Upcoming Cell & Gene Management Meeting on the Mesa
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue...
Sep 28, 2021 08:00 am ET
AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal Degeneration
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases, today announced a...
Sep 27, 2021 08:00 am ET
AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that...
Sep 23, 2021 04:05 pm ET
AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced...
Sep 16, 2021 08:00 am ET
AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results Conference Call and Webcast on September 23, 2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that...
Sep 09, 2021 08:00 am ET
AGTC to Participate in Clinical Trials in Rare Diseases Conference Panel and Case Study
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced...
Sep 08, 2021 08:00 am ET
AGTC is Excited to Announce Seasoned Healthcare Financial and Operations Executive Jonathan I. Lieber as their new Chief Financial Officer
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced Jonathan I. Lieber as...
Sep 07, 2021 10:23 am ET
AGTC to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be...
Sep 02, 2021 09:41 am ET
AGTC to Present at the 2021 Wells Fargo Virtual Healthcare Conference
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be...
Aug 24, 2021 08:00 am ET
Greater Gift, AGTC, and 2020 On-site Partner To Honor & Celebrate Clinical Trial Participants and Provide Eye Exams to Underserved Children in the Local Community
Greater Gift of Winston Salem, a non-profit that celebrates participation in clinical trials today announced a partnership with Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company developing genetic therapies for the...
Aug 19, 2021 04:05 pm ET
AGTC Announces Sponsorship of Achroma Corp’s No Roadblocks Program
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced it will be a sponsor...
Aug 18, 2021 08:00 am ET
AGTC Appoints Ophthalmology and Retinal Disease Specialist and Industry R&D Veteran Yehia Hashad, MD to its Board of Directors
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced the addition of Yehia...
Aug 16, 2021 08:00 am ET
AGTC to Participate in Envision Virtual Conference East 2021 Panel Discussion
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that...
Aug 02, 2021 04:05 pm ET
AGTC to Participate at Upcoming Investor Conferences
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that management will...
Jul 08, 2021 07:00 am ET
AGTC to Host Virtual R&D Day on July 22, 2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it will host a...
Jun 24, 2021 07:00 am ET
AGTC Reports 12-Month Data from its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today reported 12-month data from its...
Jun 23, 2021 04:03 pm ET
AGTC to Host Conference Call on June 24 at 8:00 AM ET to Discuss Achromatopsia 12-Month Data in its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it plans to...
Jun 22, 2021 07:00 am ET
AGTC to Present at American Optometric Association’s Optometry’s Meeting  
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that Jill Dolgin,...
Jun 15, 2021 09:31 am ET
Thinking about buying stock in Eloxx Pharmaceuticals, Sio Gene Therapies, Ampio Pharmaceuticals, Applied Genetic Technologies, or Cyclo Therapeutics?
NEW YORK, June 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ELOX, SIOX, AMPE, AGTC, and CYTH.
May 26, 2021 07:00 am ET
AGTC Expands Leadership Team with Appointment of Key Regulatory Leader
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced the appointment of...
May 17, 2021 04:05 pm ET
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced financial results for...
May 14, 2021 07:30 am ET
Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical proof-of-concept results for OTO-825 presented at the American Society of Gene & Cell...
May 13, 2021 04:03 pm ET
AGTC Announces Expansion of Manufacturing and Analytics Capabilities to Advance Commercialization of Gene Therapy Product Candidates
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has initiated plans...
May 11, 2021 04:05 pm ET
AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 17, 2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it will report...
May 11, 2021 07:00 am ET
AGTC Reports Process Development Advances for Manufacturing its XLRP Gene Therapy Candidate in Two Abstracts at ASGCT
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the presentation of new data...
May 06, 2021 07:00 am ET
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinical Trial
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today reported additional positive...
May 05, 2021 04:05 pm ET
AGTC to Host Conference Call on May 6 at 8:00 AM ET to Discuss XLRP Full 12-Month Data from Highest Dose Groups and 24-Month Data from a Subset of Group 4 Patients of its Ongoing Phase 1/2 Clinical Tr
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it plans to...
May 04, 2021 08:00 am ET
AGTC Advances in AAV Gene Therapy Manufacturing to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the presentation of two...
May 03, 2021 08:39 am ET
AGTC Clinical Investigators Provide Encore Presentation of Data from the Company’s Ongoing XLRP and Achromatopsia Phase 1/2 Trials
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced an encore presentation of...
Apr 29, 2021 07:30 am ET
AGTC Announces Data to be Presented from the Ongoing XLRP and Achromatopsia Clinical Trials at the ARVO 2021 Virtual Annual Meeting
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that data from the ongoing...
Apr 28, 2021 07:30 am ET
Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the upcoming presentation of preclinical proof-of-concept data for OTO-825 at the American Society of...
Apr 26, 2021 04:02 pm ET
AGTC Announces Departure of Chief Scientific Officer
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Mark Shearman, Ph.D.,...
Apr 19, 2021 07:00 am ET
AGTC licenses Promoter Technology to SparingVision SAS
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced a licensing agreement that...
Apr 13, 2021 07:00 am ET
TeamedOn and AGTC Announce a Licensing Agreement Advancing X-Linked Retinoschisis Gene Therapy Program
TeamedOn International, Inc., a biotechnology company dedicated to advancing gene therapies for rare diseases, including ophthalmic indications, and Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human...
Mar 31, 2021 08:00 am ET
AGTC to Participate in Upcoming Virtual Biotech Corporate Access Day and Cell and Gene Conference
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Company management will...
Mar 25, 2021 07:00 am ET
AGTC Announces New Initiatives To Enhance The Patient Journey In Its XLRP Trials
Applied Genetics Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, which include X-linked retinitis pigmentosa...
Mar 18, 2021 12:00 pm ET
AGTC to Present at the Gene Therapy Patient Engagement Summit, Held Virtually, March 24, 2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Jill Dolgin, PharmD,...
Mar 02, 2021 07:00 am ET
AGTC to Present at Upcoming Investor Conferences
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be...
Feb 16, 2021 12:00 pm ET
AGTC to Present at the OIS Gene Therapy Innovation Showcase on February 18, 2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President &...
Feb 16, 2021 08:00 am ET
AGTC to Present at the 4th Annual Gene Therapy for Rare Disorders Digital Event, February 22-25, 2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Dave Knop, Vice...
Feb 11, 2021 07:00 am ET
AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2020
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the...
Feb 04, 2021 12:02 pm ET
AGTC Executives Awarded First Place in the BioProcess International Reader’s Choice Awards, Cell & Gene Therapies Category
based gene therapies GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene...
Feb 04, 2021 07:00 am ET
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 11, 2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial...
Jan 28, 2021 08:07 am ET
AGTC Announces Pricing of Public Offering of Common Stock and Warrants
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the pricing of its previously...
Jan 27, 2021 04:35 pm ET
AGTC Announces Proposed Public Offering of Common Stock and Warrants
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it is offering to sell...
Jan 27, 2021 04:19 pm ET
AGTC Announces First Reported Improvements in Visual Sensitivity for Achromatopsia (ACHM) patients from its Ongoing Clinical Trials
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, is today providing an update on its ongoing...
Jan 06, 2021 04:01 pm ET
AGTC to Participate in the H.C. Wainwright BioConnect 2021 Conference
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that Sue Washer, President &...
Nov 16, 2020 04:05 pm ET
AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2020
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the...
Nov 11, 2020 07:00 am ET
AGTC Reports Additional Positive Data from its Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today reported positive data from its ongoing...
Nov 10, 2020 04:05 pm ET
AGTC to Host Conference Call on November 11 at 8:00 am ET to Discuss XLRP 12-Month Data and Full 6-Month Data from Highest Dose Groups of its Ongoing Phase 1/2 Clinical Trial
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it plans to release...
Oct 21, 2020 07:00 am ET
AGTC to Participate in Cantor Fitzgerald Virtual Panel: Key Considerations for Gene Therapy Manufacturing and Platforms
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that Sue Washer, President &...
Oct 08, 2020 07:00 am ET
AGTC to Present at Upcoming Virtual Conferences
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that management will participate...
Oct 07, 2020 07:00 am ET
AGTC Joins the My Retina Tracker® Program as a New Scientific Collaborator
Applied Genetic Technologies Corporation (AGTC), Blueprint Genetics, and Foundation Fighting Blindness, announce today that AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the...
Sep 09, 2020 07:00 am ET
AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today provided additional information about...
Sep 03, 2020 04:05 pm ET
AGTC to Participate at Upcoming Virtual Investor Conferences
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that management will be...
Sep 02, 2020 04:05 pm ET
AGTC to Host Management Update on September 9 at 8:00 am ET to Discuss Planned Phase 2/3 XLRP Trial, Share Additional XLRP Data and Report Fourth Quarter and Fiscal Year End 2020 Financial Results
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will provide a...
Aug 25, 2020 07:00 am ET
AGTC Announces Publication of Preclinical Data that Support the Ongoing Clinical Development of Its XLRP Gene Therapy Program
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that preclinical data...
Aug 12, 2020 07:00 am ET
AGTC Formalizes Patient Advisory Council to Provide Insights and Guidance on Patient Perspectives for Pipeline Therapies
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced the formation of a Patient...
Aug 04, 2020 07:00 am ET
AGTC to Present at the Wedbush PacGrow Virtual Healthcare Conference on August 11, 2020
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President &...
Jul 22, 2020 07:00 am ET
AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced next steps in the clinical...
Jun 24, 2020 07:00 am ET
AGTC Set to Join Russell 3000® and 2000® Indexes
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that the Company will be...
Jun 22, 2020 07:00 am ET
AGTC Announces Significant Productivity and Quality Enhancement To Its Proprietary Manufacturing Process
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today provided an update on the continued...
Jun 16, 2020 04:01 pm ET
AGTC to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference on June 23, 2020
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President &...
Jun 16, 2020 07:00 am ET
Bionic Sight, LLC Doses First Patient in a Phase 1/2 Clinical Trial of a New Investigational Treatment for Blindness caused by Retinitis Pigmentosa
Bionic Sight, LLC announced today that it has dosed the first patient in the Company’s Phase 1/2 clinical trial of BS01, an optogenetic gene therapy for patients with Retinitis Pigmentosa. This is an important step toward bringing BS01 forward as a...
Jun 15, 2020 07:00 am ET
AGTC Launches Nationwide Mobile Vision Testing Program for Patients Enrolled in Its Ongoing Phase 1/2 Clinical Trials
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the launch of an innovative...
May 20, 2020 07:00 am ET
AGTC Announces Publication of Positive Preclinical Data that Provides Foundational Scientific Evidence for its Ongoing Clinical Program in Patients with X-Linked Retinitis Pigmentosa (XLRP)
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the publication of positive...
May 13, 2020 07:00 am ET
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2020
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the...
May 12, 2020 08:00 am ET
Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical results from the company’s gene therapy collaboration with Applied Genetic Technologies...
May 06, 2020 07:00 am ET
AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 13, 2020
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial...
Mar 16, 2020 07:00 am ET
AGTC Announces Completion of Enrollment in All Adult Dose Groups of its Ongoing Phase 1/2 Clinical Trials in Patients with Achromatopsia
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has completed the...
Feb 19, 2020 07:00 am ET
AGTC Announces Completion of Enrollment in the Two Highest Dose Groups of its Ongoing Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has completed...
Feb 06, 2020 08:06 pm ET
AGTC Announces Pricing of $32,500,000 Public Offering of Common Stock
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the pricing of its previously...
Feb 05, 2020 04:36 pm ET
AGTC Announces Proposed Public Offering of Common Stock
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has commenced an...
Jan 28, 2020 07:30 am ET
Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical results from the company’s gene therapy collaboration with Applied Genetic Technologies...
Jan 23, 2020 07:00 am ET
AGTC Reports Encouraging Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing Phase 1/2 Clinical Trials in Achromatopsia
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today reported encouraging interim six-month...
Jan 22, 2020 04:01 pm ET
AGTC to Host Conference Call and Webcast on January 23 at 8:00 am ET to Discuss Achromatopsia Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it plans to release...
Jan 21, 2020 07:00 am ET
AGTC Announces Agenda for R&D Day on January 28, 2020 in New York
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will host an R&D Day...
Jan 09, 2020 07:00 am ET
AGTC Reports Positive Six-Month Data from its Ongoing Phase 1/2 Clinical Trial in X-Linked Retinitis Pigmentosa
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today reported positive interim six-month...
Jan 08, 2020 04:01 pm ET
AGTC to Host Conference Call and Webcast on January 9 at 8:00 am ET to Discuss X-Linked Retinitis Pigmentosa Interim Six-Month Data from the Dose Expansion Cohort of its Ongoing Phase 1/2 Clinical Tri
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it plans to release...
Dec 02, 2019 04:35 pm ET
AGTC Announces Departure of Chief Medical Officer, Company on Track to Announce XLRP and ACHM Data in January 2020
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Theresa Heah, M.D.,...
Nov 12, 2019 04:01 pm ET
AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2019
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the...
Nov 06, 2019 07:00 am ET
AGTC to Host First Quarter Results Conference Call and Webcast on November 12, 2019
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial...
Nov 05, 2019 07:00 am ET
AGTC Announces Stargardt Disease as its Second Preclinical Ophthalmology Program and Reports Compelling Preclinical Data Supporting the Potential of its Dual-Vector Technology
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has identified...
Oct 21, 2019 07:00 am ET
AGTC Presents Data Demonstrating Efficiency of its AAV Vectors for Ocular Gene Therapy Even in the Presence of Anti-AAV Antibodies
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today reported new data from non-clinical...
Oct 01, 2019 07:30 am ET
AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, and Otonomy, Inc. (NASDAQ: OTIC), a...
Sep 26, 2019 04:01 pm ET
AGTC Announces Financial Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2019
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the...
Sep 25, 2019 04:05 pm ET
AGTC to Present at Upcoming Conferences
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be...
Sep 18, 2019 04:05 pm ET
AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 26, 2019
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial...
Aug 28, 2019 07:00 am ET
AGTC to Present at Upcoming Conferences
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be...
Aug 14, 2019 07:30 am ET
Italian Achromatopsia Association Increases Global Awareness of Achromatopsia, a Rare Genetic Eye Disease, With an Expedition to Pingelap, the Island of the Color Blind
The Italian Achromatopsia Association (IAA) today announced that it is organizing a trip to Pingelap, a remote Micronesian atoll in the South Pacific, also known as the “Island of the Color Blind.” While the incidence of achromatopsia, a rare...
Aug 07, 2019 07:00 am ET
AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 14, 2019
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President &...
Jul 23, 2019 07:00 am ET
AGTC Completes Enrollment of Third Group in the Dose Escalation Portion of the Achromatopsia CNGA3 Phase 1/2 Clinical Study
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has completed...
Jun 25, 2019 07:00 am ET
AGTC Announces New Leadership Appointments
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the appointment of Theresa...
Jun 18, 2019 07:00 am ET
AGTC to Present at BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference on June 25, 2019
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President &...
May 07, 2019 07:00 am ET
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2019
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the...
Apr 30, 2019 07:00 am ET
AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 7, 2019
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial...
Apr 08, 2019 07:00 am ET
AGTC Announces Reaching Enrollment Milestones in Phase 1/2 Clinical Trials
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has achieved...
Feb 07, 2019 07:00 am ET
AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2018
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the...
Jan 31, 2019 07:00 am ET
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 7, 2019
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial...
Jan 02, 2019 07:30 am ET
New Research: Key Drivers of Growth for Hewlett Packard Enterprise, Micron Technology, Cirrus Logic, Applied Genetic Technologies, KemPharm, and Communications — Factors of Influence, Major Initiative
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Hewlett Packard Enterprise Company (NYSE:HPE), Micron Technology, Inc....
Dec 12, 2018 04:01 pm ET
AGTC Announces Topline Interim Six-Month Data from Phase 1/2 X-Linked Retinoschisis Clinical Study; Termination of Biogen Collaboration
Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today reported topline interim six-month data...
Nov 15, 2018 08:45 am ET
Consolidated Research: 2018 Summary Expectations for Tapestry, Mallinckrodt public limited company, Moxian, Applied Genetic Technologies, VistaGen Therapeutics, and Oasis Midstream Partners LP — Funda
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Tapestry, Inc. (NYSE:TPR), Mallinckrodt public limited company...
Nov 08, 2018 07:00 am ET
AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2018
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the...
Nov 01, 2018 07:00 am ET
AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 8, 2018
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial...
Sep 27, 2018 07:00 am ET
AGTC to Present at Upcoming Conferences
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced management will be...
Sep 24, 2018 05:15 pm ET
AGTC Appoints William Aliski to its Board of Directors
Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced it has appointed William...
Sep 10, 2018 04:03 pm ET
AGTC Announces Financial Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2018
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the...
Aug 30, 2018 04:05 pm ET
AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 10, 2018
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial...
Aug 08, 2018 04:05 pm ET
AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 15, 2018
Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President...
Aug 07, 2018 08:00 am ET
Achroma Corp. Announces Global Survey Results of 226 People with Achromatopsia
Achroma Corp., a non-profit 501(c)(3) tax-exempt charity dedicated to raising awareness and finding a cure for a rare form of blindness called Achromatopsia, announced results of a new global survey, Understanding the Achromatopsia Patient...
Jul 23, 2018 07:00 am ET
AGTC Treats First Patient of Second Cohort in Phase 1/2 Clinical XLRP Study; Earns $10 Million Enrollment Milestone
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has enrolled the first...
Jun 14, 2018 04:01 pm ET
AGTC Announces Expansion of Clinical and Regulatory Leadership Teams
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the appointments of Lanita C....
May 08, 2018 04:05 pm ET
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2018
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the...
Apr 30, 2018 07:00 am ET
AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 8, 2018
GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that...
Apr 18, 2018 07:00 am ET
AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that...
Apr 10, 2018 09:30 am ET
AGTC Announces Completion of Enrollment of Phase 1 / 2 Clinical Study of Investigational Gene Therapy in Patients with X-linked Retinoschisis (XLRS)
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 10, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the...
Feb 14, 2018 04:05 pm ET
AGTC Announces Sue Washer, CEO, Elected to Biotechnology Innovation Organization’s Board of Directors
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the...
Feb 09, 2018 07:00 am ET
AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2017
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial...
Feb 09, 2018 06:30 am ET
Applied Genetic Technologies Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 9, 2018 / Applied Genetic Technologies Corp. (NASDAQ: AGTC) will be discussing their earnings results in their Q2 Earnings Call to be held on February 9, 2018 at 8:00 AM Eastern Time.
Feb 01, 2018 04:05 pm ET
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 9, 2018
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that...
Dec 11, 2017 04:20 pm ET
AGTC to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14, 2017
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that...
Nov 07, 2017 04:05 pm ET
AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2017
GAINESVILLE, Fla., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended September 30, 2017....
Nov 07, 2017 04:05 pm ET
AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2017
GAINESVILLE, Fla., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the...
Sep 05, 2017 05:53 pm ET
AGTC Appoints Matthew Feinsod, M.D. as Interim Chief Medical Officer
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the appointment of Matthew Feinsod, M.D. as Interim Chief Medical Officer. Dr. Feinsod, who previously served as AGTC’s Product Development Officer, will replace Michael Goldstein, M.D. who is leaving to pursue other career opportunities....
Aug 31, 2017 07:00 am ET
AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 13, 2017
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases, today announced that it will report financial results for the fiscal quarter and year ended June 30, 2017 before the market opens on Wednesday, September 13, 2017. AGTC management will host a conference call beginning at 8:00 am ET that day to review results and provide a corporate update....
Aug 15, 2017 07:00 am ET
AGTC and the Foundation Fighting Blindness Announce Partnership Agreement
GAINESVILLE, Fla. and CAMBRIDGE, Mass. and COLUMBIA, Md., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Applied Genetics Technology Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, and the Foundation Fighting Blindness (FFB) announced today a partnership agreement to support the organizations’ shared mission to advance gene therapy research to treat inherited retinal diseases....
Aug 08, 2017 07:00 am ET
AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 16, 2017
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 16, 2017 at 9:45am ET in New York....
Aug 07, 2017 07:00 am ET
Research Published in Molecular Therapy Identifies Optimal Gene-based Therapeutic Construct for X-Linked Retinitis Pigmentosa
GAINESVILLE, Fla. and CAMBRIDGE, Mass. and PHILADELPHIA, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Researchers from the University of Pennsylvania today announced the publication of preclinical proof of concept data supporting the clinical development of a gene-based therapy for the treatment of X-linked retinitis pigmentosa (XLRP), one of the most common inherited retinal disorders, which causes progressive vision loss in boys and young men....
Jun 08, 2017 04:01 pm ET
AGTC Announces Topline Safety Data for X-Linked Retinoschisis Phase 1/2 Study
GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 08, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced topline safety data for the dose escalation phase of the company’s Phase 1/2 X-linked retinoschisis (XLRS) clinical trial, a program partnered with Biogen. Clinical investigator Mark Pennesi, M.D., Ph.D., Associate Professor in Ophthalmic Genetics and Chief of the Ophthalmic Genetics division at Oregon He...
May 10, 2017 04:07 pm ET
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2017
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended March 31, 2017....
Feb 10, 2017 04:01 pm ET
AGTC Selected as Top Company in the University of Florida’s 2017 Gator100
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Feb. 10, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that the company has been selected as the top company in the 2017 Gator100 awards....
Feb 08, 2017 04:10 pm ET
AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2016
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended December 31, 2016....
Feb 02, 2017 07:15 am ET
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 8, 2017
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial results for the quarter ended December 31, 2016 after the market closes on Wednesday, February  8, 2017. AGTC management will host a conference call beginning at 4:30 pm Eastern Time that day to review results and provide a corporate update....
Nov 17, 2016 04:01 pm ET
AGTC Appoints Michael Goldstein, M.D. as Chief Medical Officer
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the appointment of Michael Goldstein, M.D., M.B.A. as Chief Medical Officer (CMO) effective as of December 1, 2016. Dr. Goldstein will be responsible for leading the company’s clinical trials, providing medical oversight, and contributing to the overall strategic direction of the company. AGTC’s curren...
Nov 08, 2016 04:09 pm ET
AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2016
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended September 30, 2016....
Oct 27, 2016 07:00 am ET
AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 8, 2016
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial results for the quarter ended September 30, 2016 after the market closes on Tuesday, November 8, 2016. AGTC management will host a conference call beginning at 5:00 pm Eastern Time that day to review results and provide a corporate update....
Oct 19, 2016 04:01 pm ET
AGTC Files Investigational New Drug Application for the Treatment of Achromatopsia Caused by Mutations in the CNGA3 Gene
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has filed an Investigational New Drug application (IND) with the U.S. Food and Drug Administration to conduct a Phase I/II clinical trial of the Company's gene therapy product candidate for the treatment of achromatopsia caused by mutations in the CNGA3 gene. The Company previously initiated a P...
Oct 04, 2016 07:00 am ET
AGTC to Present at Upcoming Scientific Conferences
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced participation in three upcoming scientific conferences....
Sep 12, 2016 04:22 pm ET
AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30, 2016
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended June 30, 2016....
Sep 01, 2016 07:00 am ET
AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 12, 2016
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial results for the fiscal quarter and year ended June 30, 2016 after the market closes on Monday, September 12, 2016. AGTC management will host a conference call beginning at 5:00 pm Eastern Time that day to review results and provide a corporate update....
Aug 18, 2016 04:01 pm ET
AGTC Appoints Anne M. VanLent to its Board of Directors
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced it has appointed Anne M. VanLent to the company's Board of Directors....
Aug 09, 2016 07:00 am ET
AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 16th, 2016
GAINESVILLE, Fla., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that Sue Washer, President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 16th, 2016 at 1:20pm ET in New York....
Aug 02, 2016 07:00 am ET
AGTC and the Medical College of Wisconsin Announce Publication of Natural History Study Data Evaluating Residual Photoreceptor Cone Status in Patients with CNGB3-associated Achromatopsia
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, and the Medical College of Wisconsin (MCW) today announced the publication of data from studies evaluating the density of cone photoreceptors in patients with CNGB3-associated achromatopsia (ACHM). The peer-reviewed study results appear in the current issue of Investigative Ophthalmology and Visual Science....
Jul 21, 2016 07:00 am ET
AGTC Announces Presentations in Upcoming Scientific Conferences
GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 21, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced participation in two upcoming scientific conferences....
Jul 07, 2016 07:00 am ET
AGTC to Present at the Cantor Fitzgerald Second Annual Healthcare Conference on July 13, 2016
GAINESVILLE, Fla., July 07, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that Mark S. Shearman, Ph.D., Chief Scientific Officer will present at the Cantor Fitzgerald Second Annual Healthcare Conference on Wednesday, July 13th, 2016 at 11:45am ET in New York.  ...
Jun 09, 2016 07:00 am ET
AGTC to Host Research Day on June 21, 2016 in New York
GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 09, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will host a Research Day in New York City on June 21, 2016. AGTC management will be joined by two of its scientific collaborators to discuss the range of ophthalmology clinical endpoints, how they are measured, how they define and describe the vision experienced by the patient, and how results ...
Jun 07, 2016 07:00 am ET
AGTC Announces Orphan Medicinal Product Designation in the European Union for Gene Therapy to Treat X-linked Retinitis Pigmentosa
GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 07, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that the European Commission (EC) has granted an orphan medicinal product designation to its investigational gene therapy product candidate for the treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.